Présentation de l'entreprise
Neuphoria Therapeutics Inc. operates as a clinical stage biopharmaceutical entity dedicated to the discovery and development of novel allosteric ion channel modulators designed for the treatment of central nervous system disorders within the Australian market. The company functions within the broader Healthcare sector and specifically the Biotechnology industry, positions that imply a focus on high-risk, high-reward research and development phases rather than mature commercial operations. As of the latest data, Neuphoria Therapeutics Inc. maintains a market capitalization of $25.34M and reports an annual revenue of $14.99M while employing a team of 7 individuals. The combination of a market cap significantly lower than the reported annual revenue suggests a very small-scale operation where the current valuation reflects the early-stage nature of its product pipeline, specifically the lead candidate BNC210, rather than established cash flow generation. This financial structure indicates that the company's primary value proposition currently resides in its intellectual property and potential future approvals rather than existing market share or profitability.
Santé financière
The financial performance of Neuphoria Therapeutics Inc. over the trailing twelve months (TTM) demonstrates a revenue of $14.99M alongside a net income of $-5,663,908 and an EBITDA of $-1,199,915. The substantial negative gap between the $14.99M in revenue and the $-5.66M net income reveals a cost structure characterized by high operating expenses relative to sales, typical for biotechnology firms in the clinical development phase where research and development costs often outweigh current income. The company reports a free cash flow of $-803,346, which indicates a continuous burn rate that requires external capital injection to sustain operations and fund further clinical trials. Analysis of the three key margin metrics shows a gross margin of 100.0%, an operating margin of -12.4%, and a profit margin of -37.8%; the perfect gross margin suggests a service-based or early-stage manufacturing model with no direct cost of goods sold yet, while the negative operating and profit margins confirm that overhead and administrative costs are consuming the entire revenue stream. Regarding solvency, the company holds $22.17M in cash against $33,465 in total debt, resulting in a debt-to-equity ratio of 0.11, which signifies a highly conservative balance sheet with negligible leverage and minimal interest obligations. The current ratio stands at 9.04, a figure that indicates exceptional short-term liquidity, meaning the company possesses more than nine times the current assets necessary to cover its current liabilities without immediate risk of insolvency. Return on Equity is recorded at -26.1% and Return on Assets at -4.3%, metrics that reveal management is currently generating negative returns on the capital invested, a common characteristic for clinical-stage biotechs that have not yet achieved product milestones.
Évaluation de la valorisation
Valuation metrics for Neuphoria Therapeutics Inc. present a unique picture due to the absence of traditional earnings multiples; the trailing P/E ratio is listed as N/A because the company is not currently profitable, while the forward P/E is reported as -1.22, a figure that implies negative expected earnings in the near term rather than a standard multiple. The price-to-book ratio is 0.85, indicating that the market values the company at approximately 15% below its book value, which often suggests the market is discounting the firm for its lack of profitability or viewing its assets as undervalued relative to its market price. Alternative valuation measures such as the price-to-sales ratio of 1.69 and an EV/EBITDA of -2.67 are utilized instead of earnings multiples, suggesting that investors are pricing the company based on its sales potential and asset base rather than current profitability. The stock has experienced significant volatility, trading between a 52-week high of $21.40 and a 52-week low of $3.65. Without a specific current share price provided in the facts to calculate the exact percentage deviation, the trading range itself highlights the speculative nature of the asset, where the price can fluctuate dramatically from the low of $3.65 to the high of $21.40. The beta value is listed as N/A, which means volatility data relative to the broader market is not available or applicable for this specific security in the current reporting period.
Growth & Income
Growth metrics for Neuphoria Therapeutics Inc. are not available in the standard sense, as revenue growth year-over-year and earnings growth year-over-year are both listed as N/A. The absence of historical growth data for these specific periods implies that the company is likely in a stage where year-over-year comparisons are either not meaningful due to early revenue recognition or the data points are not yet established for the reporting cycle. Since the company reports a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute earnings to shareholders, which is consistent with a firm that retains all resources to fund its clinical development and operational expenses. Consequently, the company reinvests its entire cash flow, including its $22.17M cash reserve, directly into its research and development activities rather than generating income through dividend payments. The overall growth and income profile is defined by a total lack of current profitability and dividend income, focusing entirely on capital appreciation potential derived from future product approvals and the successful advancement of its lead product candidate BNC210.